Accès ouvert
2024
article
OpenAlex
Charlotte L. van Veldhuisen, Marinus Abraham Kempeneers, Florence E.M. de Rijk, Stefan A.W. Bouwense et autres
Importance: Patients with painful chronic pancreatitis and a dilated pancreatic duct can be treated by early surgery or an endoscopy-first approach. Objective: To compare long-term clinical outcomes of early surgery vs an endoscopy-first approach using follow-up data from the ESCAPE randomized clinical …
nl, us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Pieter H.A. Wisse, Sybrand Y. de Boer, Marco Oudkerk Pool, Jochim S. Terhaar sive Droste et autres
Abstract Background Post-colonoscopy colorectal cancers (PCCRCs) decrease the effect of colorectal cancer (CRC) screening programs. To enable PCCRC incidence reduction in the long-term, we classified PCCRCs diagnosed after colonoscopies performed in a fecal immunochemical test (FIT)-based screening program. Methods PCCRCs diagnosed after …
nl
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Femke Crouwel, Ahmed B. Bayoumy, Chris J. Mulder, Job Peters et autres
BACKGROUND: Currently thioguanine is solely used as treatment for inflammatory bowel disease after azathioprine and/or mercaptopurine failure. This study aimed to determine the safety, effectiveness, and 12-month drug survival of thioguanine in thiopurine-naïve patients with inflammatory bowel disease. METHODS: A retrospective cohort …
nl
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Pieter H.A. Wisse, Nicole Stephanie Erler, Sybrand Y. de Boer, Bert den Hartog et autres
BACKGROUND: The adenoma detection rate (ADR) is an essential quality indicator for endoscopists performing colonoscopies for colorectal cancer (CRC) screening as it is associated with postcolonoscopy CRCs (PCCRCs). Currently, data on ADRs of endoscopists performing colonoscopies in fecal immunochemical testing (FIT)-based screening, …
nl
(code pays fourni par la source)
Accès ouvert
2022
conference-abstract
OpenAlex
Femke Crouwel, Ahmed B. Bayoumy, Chris J J Mulder, Job Peters et autres
Abstract Background Currently thioguanine is considered as off-label rescue therapy for Inflammatory Bowel Disease (IBD) after conventional thiopurine failure. This study aimed to determine the safety, effectiveness and 12-month drug tolerability of thioguanine in thiopurine-naïve IBD patients. Methods We performed an analysis …
nl
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Christoph Engel, Hans F. A. Vasen, Toni T. Seppälä, Stefan Aretz et autres
de, nl, fi
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Melek Simsek, Berrie Meijer, Dewkoemar Ramsoekh, Gerd Bouma et autres
nl
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Loes H.C. Nissen, Lauranne A. A. P. Derikx, A Jacobs, Carla ML van Herpen et autres
Background: Immunosuppressed inflammatory bowel disease (IBD) patients are at increased risk to develop extra-intestinal malignancies. Immunosuppressed transplant patients show increased incidence of head and neck cancer with impaired survival. This study aims to identify risk factors for oral cavity (OCC) and pharyngeal …
nl
(code pays fourni par la source)
2009
article
OpenAlex
W. F. Lam, Ad Masclee, Sybrand Y. de Boer, Cornelis B.H.W. Lamers
We have investigated the effect of acute stable hyperglycemia on gastric acid secretion and serum gastrin and pancreatic polypeptide (PP) release. Gastric acid output was measured under basal conditions and in response to modified sham feeding (MSF) in 7 healthy volunteers on …
nl
(code pays fourni par la source)
Accès ouvert
2007
article
OpenAlex
Mariken J. Tijhuis, Marleen H. P. W. Visker, Jac M. M. J. G. Aarts, Wijnand Laan et autres
Both environment and genetics contribute to the pathogenesis and prevention of colorectal neoplasia. NAD(P)H: quinone oxidoreductase (NQO1) is a detoxification enzyme that is polymorphic and inducible. We investigated interactions between lifestyle factors and polymorphisms in NQO1 and its key regulatory transcription factor …
nl
(code pays fourni par la source)
2007
article
OpenAlex
Dirk J. de Jong, D. J. Bac, Gie Tan, Sybrand Y. de Boer et autres
BACKGROUND: In previous trials, budesonide 6 mg/day was able to prolong the time to relapse in patients with quiescent Crohn's disease and budesonide 9 mg/day was effective in active disease with limited side effects. The aim of this study was to compare …
nl
(code pays fourni par la source)
Accès ouvert
2007
article
OpenAlex
Maureen van den Donk, Linette Pellis, Jimmy W. Crott, Manon van Engeland et autres
nl, us
(code pays fourni par la source)